CRNX News and Press, Crinetics Pharmaceuticals Inc. From 04/14/20

Gainers: UAL   +7.5% .   PVAC   +6.7% . AAL   +6.7% . GME   +6.6%.  FHN   +5.9% . More news on: United Airlines Holdings, Inc., Penn Virginia Corporation, American Airlines Group Inc., Stocks on the move, , Read more ...

Crinetics Pharmaceuticals (NASDAQ: CRNX ) initiates a public offering of common stock. Price, volume and terms have yet to be announced. More news on: Crinetics Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today t...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Mesoblast Gets FDA Go-Ahead for COVID 19 Treatment Application Mesoblast Limited ( MESO ) announced that the US FDA has cleared its Investigational New Drug application for treating patients suffering from acute respiratory distress syndrome ((ARDS)) due to coronavirus infection using re...

Crinetics Pharmaceuticals (NASDAQ: CRNX ) reports positive interim data from a Phase 2 clinical trial, ACROBAT EDGE , evaluating oral paltusotine (CRN00808) in patients with acromegaly , a rare disorder in which the pituitary gland produces too much growth hormone which causes bones to i...

Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor l...

Crinetics Pharmaceuticals (NASDAQ: CRNX ): Q4 GAAP EPS of -$0.60 beats by $0.08 . More news on: Crinetics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced f...

The severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 for short, has definitely made its presence felt on Wall Street during the opening weeks of 2020. Despite a strong start to 2020, the  Dow Jones Industrial Average , the  Nasdaq Composite , and the  S&P 5...